Press Releases
Optimind Pharma Provides Corporate Update
TORONTO, ON / ACCESSWIRE / December 19, 2023 / Optimind Pharma Corp. (CSE:OMND) ("Optimind" or the "Company"), an emerging provider of psychedelic therapies, is pleased to announce that Manitari Pharma Corporation ("Manitari") has received its Controlled Drug and...
Optimind Acquires MindSetting Institute to Integrate Three-Pronged Approach to its Business and Become Industry Leader in Psychedelic Enhanced Psychotherapy
Optimind looks to accelerate the adoption of the MindSetting(TM) TRIP Protocol for ketamine-assisted therapy and other psychedelic enhanced psychotherapy modalities. Toronto, Ontario--(Newsfile Corp. - September 20, 2022) - Optimind Pharma Corp. (CSE: OMND)...
Optimind Provides Update on Health Canada’s Dealer License under Joint-Venture with Manitari Pharma
Optimind Provides Update on Health Canada’s Dealer License under Joint-Venture with Manitari PharmaManitari Pharma received approval to begin construction of Security Level 3 safe + grow rooms Manitari Pharma is one step closer to obtaining Controlled Substances...
Optimind Pharma Commences Trading on the CSE Under Ticker Symbol OMND
Optimind Pharma Commences Trading on the CSE Under Ticker Symbol OMNDTORONTO – Optimind Pharma Corp. (CSE:OMND (“Optimind” or the “Company”) today announced its commencement of trading on the CSE (Canadian Securities Exchange) under ticker symbol “OMND”. Optimind...
Optimind Pharma Announces Closing of Reverse Takeover Transaction
Optimind Pharma Announces Closing of Reverse Takeover TransactionToronto, Ontario--(Newsfile Corp. - July 29, 2022) - Optimind Pharma Corp. ("Optimind" or the "Company") announces the successful closing of its previously announced reverse takeover ("RTO") of Loon...